open access

Vol 76, No 6 (2018)
Original articles
Published online: 2018-01-26
Submitted: 2017-08-17
Accepted: 2018-01-26
Get Citation

MiR-130a inhibition protects rat cardiac myocytes from hypoxia-triggered apoptosis by targeting Smad4

Yuanshi Li, Yingrong Du, Junxian Cao, Qianping Gao, Hongjuan Li, Yangjun Chen, Nihong Lu
DOI: 10.5603/KP.a2018.0040
·
Kardiol Pol 2018;76(6):993-1001.

open access

Vol 76, No 6 (2018)
Original articles
Published online: 2018-01-26
Submitted: 2017-08-17
Accepted: 2018-01-26

Abstract

Background: Cardiomyocyte death facilitates the pathological process underlying ischaemic heart diseases, such as myocardial infarction. Emerging evidence suggests that microRNAs play a critical role in the pathological process underlying myocardial infarction by regulating cardiomyocyte apoptosis. However, the relevance of miR-130a in regulating cardiomyocyte apoptosis and the underlying mechanism are still uncertain.

Aim: We sought to explore the regulatory effect of miR-130a on hypoxic cardiomyocyte apoptosis.

Methods: The expression of miR-130a was measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Cell survival was determined by the MTT assay. The lactate dehydrogenase (LDH) assay was performed to deter­mine the severity of hypoxia-induced cell injury. Apoptosis was assessed via caspase-3 analysis. Protein expression level was determined by Western blotting. The genes targeted by miR-130a were predicted using bioinformatics and were validated via the dual-luciferase reporter assay system.

Results: We found that miR-130a expression was greatly increased in hypoxic cardiac myocytes, and that the downregulation of miR-130a effectively shielded cardiac myocytes from hypoxia-triggered apoptosis. In bioinformatic analysis the Smad4 gene was predicted to be the target of miR-130a. This finding was validated through the Western blot assay, dual-luciferase reporter gene assay, and qRT-PCR. MiR-130a inhibition significantly promoted the activation of Smad4 in hypoxic cardiomyocytes. Inter­estingly, knockdown of Smad4 markedly reversed the protective effects induced by miR-130a inhibition. Moreover, we found that the inhibition of miR-130a promoted the activation of transforming growth factor-b1 signalling. Blocking of Smad4 signal­ling significantly abrogated the protective effects of miR-130a inhibition.

Conclusions: The findings indicate that inhibition of miR-130a, which targets the Smad4 gene, shields cardiac myocytes from hypoxic apoptosis. This study offers a novel perspective on the molecular basis of hypoxia-induced cardiomyocyte apoptosis and suggests a possible drug target for the treatment of myocardial infarction.

Abstract

Background: Cardiomyocyte death facilitates the pathological process underlying ischaemic heart diseases, such as myocardial infarction. Emerging evidence suggests that microRNAs play a critical role in the pathological process underlying myocardial infarction by regulating cardiomyocyte apoptosis. However, the relevance of miR-130a in regulating cardiomyocyte apoptosis and the underlying mechanism are still uncertain.

Aim: We sought to explore the regulatory effect of miR-130a on hypoxic cardiomyocyte apoptosis.

Methods: The expression of miR-130a was measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Cell survival was determined by the MTT assay. The lactate dehydrogenase (LDH) assay was performed to deter­mine the severity of hypoxia-induced cell injury. Apoptosis was assessed via caspase-3 analysis. Protein expression level was determined by Western blotting. The genes targeted by miR-130a were predicted using bioinformatics and were validated via the dual-luciferase reporter assay system.

Results: We found that miR-130a expression was greatly increased in hypoxic cardiac myocytes, and that the downregulation of miR-130a effectively shielded cardiac myocytes from hypoxia-triggered apoptosis. In bioinformatic analysis the Smad4 gene was predicted to be the target of miR-130a. This finding was validated through the Western blot assay, dual-luciferase reporter gene assay, and qRT-PCR. MiR-130a inhibition significantly promoted the activation of Smad4 in hypoxic cardiomyocytes. Inter­estingly, knockdown of Smad4 markedly reversed the protective effects induced by miR-130a inhibition. Moreover, we found that the inhibition of miR-130a promoted the activation of transforming growth factor-b1 signalling. Blocking of Smad4 signal­ling significantly abrogated the protective effects of miR-130a inhibition.

Conclusions: The findings indicate that inhibition of miR-130a, which targets the Smad4 gene, shields cardiac myocytes from hypoxic apoptosis. This study offers a novel perspective on the molecular basis of hypoxia-induced cardiomyocyte apoptosis and suggests a possible drug target for the treatment of myocardial infarction.

Get Citation

Keywords

apoptosis, cardiomyocyte, hypoxia, miR-130a, Smad4

About this article
Title

MiR-130a inhibition protects rat cardiac myocytes from hypoxia-triggered apoptosis by targeting Smad4

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 76, No 6 (2018)

Pages

993-1001

Published online

2018-01-26

DOI

10.5603/KP.a2018.0040

Bibliographic record

Kardiol Pol 2018;76(6):993-1001.

Keywords

apoptosis
cardiomyocyte
hypoxia
miR-130a
Smad4

Authors

Yuanshi Li
Yingrong Du
Junxian Cao
Qianping Gao
Hongjuan Li
Yangjun Chen
Nihong Lu

References (20)
  1. McMurray JJV. Clinical practice. Systolic heart failure. N Engl J Med. 2010; 362(3): 228–238.
  2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353(9146): 9–13.
  3. Li X, Liu M, Sun R, et al. Protective approaches against myocardial ischemia reperfusion injury. Exp Ther Med. 2016; 12(6): 3823–3829.
  4. Yamamura Y, Hua X, Bergelson S, et al. Critical role of Smads and AP-1 complex in transforming growth factor-beta -dependent apoptosis. J Biol Chem. 2000; 275(46): 36295–36302.
  5. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958): 577–584.
  6. Wu L. Functional characteristics of a novel SMAD4 mutation from thoracic aortic aneurysms (TAA). Gene. 2017; 628: 129–133.
  7. Zhu Y, Wu G, Yan W, et al. miR-146b-5p regulates cell growth, invasion, and metabolism by targeting PDHB in colorectal cancer. Am J Cancer Res. 2017; 7(5): 1136–1150.
  8. Yang J, Wang J, Zeng Z, et al. Smad4 is required for the development of cardiac and skeletal muscle in zebrafish. Differentiation. 2016; 92(4): 161–168.
  9. Häger M, Pedersen CC, Larsen MT, et al. MicroRNA-130a-mediated down-regulation of Smad4 contributes to reduced sensitivity to TGF-β1 stimulation in granulocytic precursors. Blood. 2011; 118(25): 6649–6659.
  10. Wu G, Huang ZP, Wang DZ. MicroRNAs in cardiac regeneration and cardiovascular disease. Sci China Life Sci. 2013; 56(10): 907–913.
  11. Wahid F, Shehzad A, Khan T, et al. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010; 1803(11): 1231–1243.
  12. Ambros V. microRNAs: tiny regulators with great potential. Cell. 2001; 107(7): 823–826.
  13. Wang Y, Du J, Niu X, et al. MiR-130a-3p attenuates activation and induces apoptosis of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2. Cell Death Dis. 2017; 8(5): e2792.
  14. Kim GH, Samant SA, Earley JU, et al. Translational control of FOG-2 expression in cardiomyocytes by microRNA-130a. PLoS One. 2009; 4(7): e6161.
  15. Ye Y, Perez-Polo JR, Qian J, et al. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics. 2011; 43(10): 534–542.
  16. Dorn GW. MicroRNAs in cardiac disease. Transl Res. 2011; 157(4): 226–235.
  17. Lin AE, Michot C, Cormier-Daire V, et al. Gain-of-function mutations in SMAD4 cause a distinctive repertoire of cardiovascular phenotypes in patients with Myhre syndrome. Am J Med Genet A. 2016; 170(10): 2617–2631.
  18. Andrabi S, Bekheirnia MR, Robbins-Furman P, et al. SMAD4 mutation segregating in a family with juvenile polyposis, aortopathy, and mitral valve dysfunction. Am J Med Genet A. 2011; 155A(5): 1165–1169.
  19. Ziemke M, Patil T, Nolan K, et al. Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer. 2017; 109: 28–35.
  20. Duan Y, Zhu W, Liu M, et al. The expression of Smad signaling pathway in myocardium and potential therapeutic effects. Histol Histopathol. 2017; 32(7): 651–659.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl